Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

150.56USD
18 Jan 2018
Change (% chg)

$1.23 (+0.82%)
Prev Close
$149.33
Open
$149.15
Day's High
$151.82
Day's Low
$147.55
Volume
82,057
Avg. Vol
85,167
52-wk High
$151.82
52-wk Low
$95.21

Select another date:

Thu, Jan 11 2018

BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS

BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects

* LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS

BRIEF-Ligand Pharmaceuticals - Expects Reduction Of Corporate Tax Rate To Reduce Deferred Tax Asset On Balance Sheet By About $40 Mln

* LIGAND PHARMACEUTICALS - EXPECTS REDUCTION OF CORPORATE TAX RATE TO REDUCE DEFERRED TAX ASSET ON BALANCE SHEET BY ABOUT $40 MILLION AS OF SEPT 30, 2017 Source text: (http://bit.ly/2zy8ap7) Further company coverage:

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

* Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​

BRIEF-Ligand Q3 adjusted earnings per share $0.69

* Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S

BRIEF-Ligand to acquire Crystal Bioscience

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments

BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

* Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody

* Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody discovered using the OmniAb technology

BRIEF-Ligand Pharmaceuticals Q2 earnings per share $0.26

* Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S

Select another date: